Church & Dwight Co., Inc. · CHD · FY2025 Q3 · Calendar Q4 2025

Church & Dwight raises EPS outlook as brands gain share

The quarter supports a constructive operating thesis: Church & Dwight is pairing resilient core-brand demand and share gains with TOUCHLAND momentum and a higher EPS outlook. The main tests are whether promotional pressure, discontinued lines, the vitamin review, and macro costs limit the durability of that progress.

Reported Before market openNYSEConsumer Defensive $22.67B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.81 Consensus $0.74
EPS surprise +10.1% Reported versus consensus
Reported revenue $1.59B Consensus $1.53B
Revenue surprise +3.4% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +7.2% Event window
SPY move +0.3% Same window
Abnormal move +6.9% Stock minus SPY
Volume 3.2× Versus trailing sessions
Subsequent drift -3.5% Up to 20 sessions
CHDSPY benchmark

Ask FN2 about CHD FY2025 Q3

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior quarter, management moved from maintained to raised guidance. Q3 added stronger organic growth, a higher full-year EPS outlook, better-than-expected TOUCHLAND performance, and a first growth period in eight quarters for ARM & HAMMER value-tier laundry.

Guidance delta

Management raised full-year adjusted EPS guidance to $3.49 and plans marketing spend above 11% of sales.

Key takeaways

  • Q3 organic sales grew 3.4% and adjusted EPS beat the outlook by $0.09.
  • TOUCHLAND exceeded expectations with double-digit consumption growth and expanding market share.
  • ARM & HAMMER value-tier laundry detergent grew for the first time in eight quarters.
  • Management raised full-year adjusted EPS guidance to $3.49 and plans marketing spend above 11% of sales.
  • The company cited continued innovation, additional M&A activity, and a January Investor Day as next steps.

Management priorities

  • Build momentum from the TOUCHLAND acquisition.
  • Invest in marketing above 11% of sales and continue core-brand innovation.
  • Launch THERABREATH toothpaste, TROJAN G.O.A.T., and additional laundry innovations.
  • Continue M&A focused on personal-care and problem-solution brands.
  • Use the January Investor Day to detail further growth initiatives.

Follow CHD with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
CHD EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $0.87 Q1 '24 actual $0.96, beat Q2 '24 estimate $0.84 Q2 '24 actual $0.93, beat Q3 '24 estimate $0.68 Q3 '24 actual $0.79, beat Q2 '25 estimate $0.86 Q2 '25 actual $0.94, beat Q3 '25 estimate $0.74 Q3 '25 actual $0.81, beat Q4 '25 estimate $0.84 Q4 '25 actual $0.86, beat Q1 '26 estimate $0.93 Q1 '26 actual $0.95, beat Q2 '26 estimate $0.90 Q2 '26 actual $0.89, match Q3 '26 estimate $0.90 Q4 '26 estimate $0.98 Q1 '27 estimate $1.00
Show 1 more >

Analyst Consensus ?

ConsensusBuy34 ratings
Bullish1853.0%
Neutral1544.1%
Bearish12.9%

Analyst 52W Price Targets

$95.66Current
$78Low
$103.69Average
$120High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 6, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 5, 2026
UBS Neutral NeutralMaintainAug 3, 2026
TD Cowen Hold HoldMaintainAug 3, 2026
RBC Capital Outperform OutperformMaintainAug 3, 2026
Citigroup Neutral NeutralMaintainAug 3, 2026
Barclays Underweight UnderweightMaintainJul 21, 2026
JP Morgan Neutral NeutralMaintainJul 16, 2026
Evercore ISI Group In Line In LineMaintainMay 4, 2026
Rothschild & Co Neutral SellUpgradeFeb 13, 2026
Morgan Stanley Equal Weight Equal WeightMaintainFeb 2, 2026
Jefferies Buy BuyMaintainFeb 2, 2026
Raymond James Outperform Market PerformUpgradeJan 5, 2026
Deutsche Bank Buy BuyMaintainDec 10, 2025
Argus Research Buy BuyMaintainDec 4, 2025
Oppenheimer Outperform OutperformMaintainOct 21, 2025
B of A Securities Buy BuyMaintainOct 8, 2025
Truist Securities Buy BuyMaintainJun 6, 2025
Stifel Hold HoldMaintainFeb 3, 2025
Piper Sandler Overweight OverweightMaintainFeb 3, 2025
HSBC Hold HoldMaintainMay 3, 2024
Goldman Sachs Buy BuyMaintainMar 4, 2024
Atlantic Equities Neutral UnderweightUpgradeFeb 6, 2023
Credit Suisse Outperform NeutralUpgradeJan 17, 2023
SunTrust Robinson Humphrey Buy BuyMaintainMay 15, 2020
Bank of America Buy BuyMaintainDec 19, 2019
Stifel Nicolaus Hold HoldMaintainAug 1, 2019
Macquarie Outperform OutperformMaintainMar 29, 2019
BMO Capital Market Perform Market PerformMaintainNov 2, 2018
Societe Generale Hold BuyDowngradeAug 7, 2018
BTIG Research Buy BuyMaintainNov 19, 2014
KeyBanc Hold HoldMaintainDec 16, 2013
Credit Agricole Outperform UnderperformUpgradeFeb 6, 2013
Wellington Shields Buy HoldUpgradeAug 24, 2012
Gabelli & Co. Hold BuyDowngradeFeb 8, 2012
Show less

Named analyst price targets

Upside is calculated against the persisted current price $95.66. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
RBC CapitalNik Modi$115$100.51 +20.2%Aug 3, 2026
Cowen & Co.Robert Moskow$97$100.49 +1.4%Aug 3, 2026
Morgan StanleyDwight to$112$101.27 +17.1%Aug 3, 2026
UBSAnalyst unavailable$107$101.3 +11.9%Aug 3, 2026
JefferiesKaumil Gajrawala$115$98.81 +20.2%Aug 3, 2026
Goldman SachsAnalyst unavailable$111$95.63 +16.0%May 29, 2026
UBSAnalyst unavailable$100$93.5 +4.5%May 4, 2026
RBC CapitalAnalyst unavailable$114$93.68 +19.2%May 4, 2026
Deutsche BankAnalyst unavailable$109$93.61 +13.9%May 4, 2026
Evercore ISIAnalyst unavailable$105$93.99 +9.8%May 4, 2026
RBC CapitalDwight to$112$96.16 +17.1%Apr 9, 2026
Wells FargoAnalyst unavailable$110$101.45 +15.0%Feb 17, 2026
Redburn PartnersEdward Lewis$91$100 -4.9%Feb 13, 2026
Morgan StanleyAnalyst unavailable$105$97.66 +9.8%Feb 2, 2026
Wells FargoAnalyst unavailable$105$96.25 +9.8%Feb 2, 2026
UBSAnalyst unavailable$92$89.1 -3.8%Jan 14, 2026
Wells FargoAnalyst unavailable$92$82.69 -3.8%Jan 5, 2026
Raymond JamesOlivia Tong$100$82.64 +4.5%Jan 5, 2026
JefferiesKaumil Gajrawala$102$84.55 +6.6%Dec 16, 2025
Deutsche BankSteve Powers$100$82.63 +4.5%Dec 10, 2025
Argus ResearchAnalyst unavailable$102$84.18 +6.6%Dec 4, 2025
BarclaysAnalyst unavailable$82$86.28 -14.3%Nov 4, 2025
OppenheimerAnalyst unavailable$100$88.08 +4.5%Oct 21, 2025
Redburn PartnersEdward Lewis$83$98.05 -13.2%Jul 14, 2025
Truist FinancialBill Chappell$110$99.16 +15.0%Jun 6, 2025
BarclaysAnalyst unavailable$97$108.39 +1.4%Mar 27, 2025
JefferiesKaumil Gajrawala$108$102.96 +12.9%Nov 4, 2024
Piper SandlerKorinne Wolfmeyer$120$103.52 +25.4%Sep 23, 2024
J.P. MorganAndrea Teixeira$97$100.08 +1.4%Aug 5, 2024
BMO CapitalPhillip Jungwirth$115$53.51 +20.2%Jun 3, 2024
CFRAAna Garcia$114$105.82 +19.2%May 3, 2024
HSBCAlejandro Zamacona$110$105.88 +15.0%May 3, 2024
OppenheimerRupesh Parikh$120$105.95 +25.4%Apr 23, 2024
Argus ResearchTaylor Conrad$115$100.4 +20.2%Feb 23, 2024
Deutsche BankSteve Powers$110$91.96 +15.0%Nov 3, 2023
Morgan StanleyDara Mohsenian$114$91.48 +19.2%Oct 23, 2023
Truist FinancialBill Chappell$105$94.44 +9.8%Aug 28, 2023
Deutsche BankAnalyst unavailable$91$83.29 -4.9%Feb 6, 2023
Morgan StanleyAnalyst unavailable$92$82.9 -3.8%Feb 6, 2023
J.P. MorganAnalyst unavailable$81$81.55 -15.3%Jan 13, 2023
Wells FargoAnalyst unavailable$90$80.96 -5.9%Jan 3, 2023
Argus ResearchJohn Stasak$78$72.59 -18.5%Nov 7, 2022
Deutsche BankSteve Powers$85$73.35 -11.1%Oct 5, 2022
JefferiesAnalyst unavailable$98$77.74 +2.4%Sep 14, 2022
Deutsche BankAnalyst unavailable$90$80.66 -5.9%Sep 7, 2022
BarclaysAnalyst unavailable$73$80.23 -23.7%Sep 7, 2022
Goldman SachsAnalyst unavailable$93$86.87 -2.8%Aug 3, 2022
BarclaysAnalyst unavailable$76$88.6 -20.6%Aug 2, 2022
Truist FinancialAnalyst unavailable$100$88.29 +4.5%Aug 1, 2022
Deutsche BankAnalyst unavailable$93$89.6 -2.8%Aug 1, 2022
UBSAnalyst unavailable$98$87.94 +2.4%Aug 1, 2022
Morgan StanleyAnalyst unavailable$82$87.86 -14.3%Aug 1, 2022
J.P. MorganAnalyst unavailable$86$92.54 -10.1%Jul 21, 2022
Wells FargoChris Carey$95$85.91 -0.7%Jun 21, 2022
BarclaysAnalyst unavailable$77$88.75 -19.5%May 23, 2022
BarclaysAnalyst unavailable$81$97.56 -15.3%May 2, 2022
BarclaysLauren Lieberman$86$103.01 -10.1%Jan 13, 2022
Wells FargoChristopher Carey$100$102.26 +4.5%Jan 5, 2022
OppenheimerRupesh Parikh$110$98.57 +15.0%Dec 20, 2021
UBSPeter Grom$89$87.16 -7.0%Nov 1, 2021
Morgan StanleyDara Mohsenian$80$86.35 -16.4%Apr 19, 2021
Show less

Track every rating change on CHD the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Church & Dwight Co., Inc. is a company dedicated to the creation, production, and marketing of a diverse portfolio encompassing household, personal care, and specialized industrial goods. Its operations are structured into three principal divisions: Consumer Domestic, Consumer International, and the Specialty Products Division. The company offers a broad array of well-known consumer brands. Under the ARM & HAMMER umbrella, it provides cat litters, carpet fresheners, laundry detergents, baking soda, and various other baking soda-based items. Sexual health products, including condoms, lubricants, and vibrators, are marketed under the TROJAN brand. OXICLEAN delivers stain removers, cleaning solutions, laundry detergents, and bleach alternatives. SPINBRUSH offers both battery-operated and manual toothbrushes. Home pregnancy and ovulation test kits are available through FIRST RESPONSE. NAIR specializes in depilatories, while ORAJEL provides oral pain relief. XTRA is another prominent laundry detergent brand.…

Historical context

All CHD earnings

Consumer Defensive peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the CHD recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-06T05:20:40.968845+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-06T05:20:40.965998+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-06. For educational purposes only; not investment advice.